Marathon Capital Management’s Chemours CC Stock Holding History

Marathon Capital Management’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,000	Closed	-$240K	–	157
2023 Q1	$240K	Buy	+8,000	New	+$264K	0.06%	137
2022 Q3	–	Sell	-8,032	Closed	-$257K	–	155
2022 Q2	$257K	Buy	+8,032	New	+$295K	0.08%	119
2022 Q1	–	Sell	-8,032	Closed	-$270K	–	106
2021 Q4	$270K	Hold	8,032	–	–	0.06%	143
2021 Q3	$234K	Hold	8,032	–	–	0.05%	198
2021 Q2	$279K	Sell	8,032 -125	-2%	-$4.14K	0.06%	145
2021 Q1	$227K	Hold	8,157	–	–	0.06%	167
2020 Q4	$202K	Buy	+8,157	New	+$194K	0.06%	148

Other funds holding CC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marathon Capital Management's CC Position: Q2 2023 in Review

Marathon Capital Management sold out of Chemours (CC) in Q2 2023, closing a stake of 8,000 shares — an estimated $240K sold.

Marathon Capital Management first reported a position in CC in Q4 2020 and held it in 7 quarters. The position peaked at $279K in Q2 2021. 476 funds tracked by Wall St. Rank hold CC as of Q2 2023.

Marathon Capital Management reported no remaining Chemours position as of Q2 2023 after selling out during the quarter.
Marathon Capital Management sold 8,000 Chemours shares in Q2 2023, an estimated $240K.
Marathon Capital Management first reported a position in Chemours in Q4 2020 and held it in 7 quarters.
Marathon Capital Management's Chemours position peaked at $279K in Q2 2021.
476 funds tracked by Wall St. Rank held Chemours as of Q2 2023.

Based on Marathon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.